Biosimilar nomenclature: Deadline August 2 for comments on FDA’s OMB information request

Meaningful suffix may be in for U.S. biologics, biosimilars     FDA Pushes Back Comment Period for Biosimilar Labeling Just released: new deadline August?2 for information collection request it submitted to the White House Office of Management and Budget (OMB)     Additional Reading FDA approves Inflectra, a biosimilar to Remicade A Rocky Start for[…]